Molecular target therapy for cancer is characterized by unique adverse effects that are not usually observed with cytotoxic chemotherapy. For example, the anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor crizotinib causes characteristic visual disturbances, whereas such effects are rare when another ALK-tyrosine kinase inhibitor, alectinib, is used. To elucidate the mechanism responsible for these visual disturbances, the responses to light exhibited by retinal ganglion cells treated with these agents were evaluated using a C57BL6 mouse ex vivo model. Both crizotinib and alectinib changed the firing rate of ON and OFF type retinal ganglion cells. However, the ratio of alectinib-affected cells (15.7%) was significantly lower than that of crizotinib-affected cells (38.6%). Furthermore, these drugs changed the response properties to light stimuli of retinal ganglion cells in some of the affected cells, i.e., OFF cells responded to both ON and OFF stimuli, etc. Finally, the expressions of ALK (a target receptor of both crizotinib and alectinib) and of MET and ROS1 (additional target receptors of crizotinib) were observed at the mRNA level in the retina. Our findings suggest that these drugs might target retinal ganglion cells and that the potency of the drug actions on the light responses of retinal ganglion cells might be responsible for the difference in the frequencies of visual disturbances observed between patients treated with crizotinib and those treated with alectinib. The present experimental system might be useful for screening new molecular target agents prior to their use in clinical trials.
Citation: Ishii T, Iwasawa S, Kurimoto R, Maeda A, Takiguchi Y, Kaneda M (2015) Crizotinib-Induced Abnormal Signal Processing in the Retina. PLoS ONE 10(8): e0135521. https://doi.org/10.1371/journal.pone.0135521
Editor: Steven Barnes, Dalhousie University, CANADA
Received: April 23, 2015; Accepted: June 13, 2015; Published: August 13, 2015
Copyright: © 2015 Ishii et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper.
Funding: This work was supported by a Grant-in-Aid for Young Scientists (B) from JSPS (KAKENHI No. 26860150) to T. Ishii, a Grant-in-Aid for Scientific Research (C) from JSPS (KAKENHI No. 26462670), and a Nippon Medical School Grant-in-Aid for Medical Research to M. Kaneda.
Competing interests: Yuchi Takiguchi received research fundings from Pfizer Japan, AstraZeneca Japan and Chugai Pharmaceutical Co., and honoraria for speech from Pfizer Japan, AstraZeneca Japan and Chugai Pharmaceutical Co. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
The development of drugs for targeted therapy has revolutionized cancer therapy. Some of these drugs promise significant responses for patients with cancers expressing the molecular target. However, these drugs have specific and unique adverse effects that differ from those of cytotoxic agents. For example, skin disorders including rashes, pruritus, and acne are seen in patients treated with gefitinib , erlotinib  and cetuximab , while severe diarrhea is seen in patients treated with afatinib .
The standard therapy for patients with non-small-cell lung cancer (NSCLC) without specific target molecules is platinum doublets, resulting in a median survival time of almost 10–14 months and a response rate of 20% to 35% [5,6]. In contrast, NSCLC expressing specific target molecules is highly sensitive to molecular target drugs. In patients with NSCLC with mutated epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitors, including gefitinib and erlotinib, have enabled a significantly longer survival time of about 30 months and higher response rates of 70% to 80% [7,8].
Anaplastic lymphoma kinase (ALK) is a target molecule for the treatment of several cancers, including NSCLC, inflammatory myofibroblastic tumor, and anaplastic large-cell lymphoma [9,10]. The fusion of the ALK gene with others, including echinoderm microtubule-associated protein-like 4 (EML4) and kinesin family member 5B (KIF5B), is observed in about 5% of patients with NSCLC [11,12]. In NSCLC with ALK rearrangements, the fused gene can lead to tumorigenesis in the absence of other oncogenes, such as mutated EGFR and KRAS . These ALK rearrangements are an important target for treatment.
Crizotinib is the first established tyrosine kinase inhibitor targeting ALK, the mesenchymal-epithelial transition (MET), and repressor of silencing 1 (ROS1) [9,14,15]. In large-scale, randomized clinical trials for patients with NSCLC with ALK rearrangements, about 60% of the patients achieved an objective response [16,17,18]. Furthermore, crizotinib is also effective against NSCLC with ROS1 rearrangements . However, a specific profile of adverse effects is seen in patients treated with crizotinib, with nausea, liver damage, and neutropenia being commonly seen. Above all, unique visual disorders can occur. Mild visual disturbances have been reported in some patients (41%-62%) participating in clinical trials [16,17,18]. Patients with these disorders usually complain of trails of light following objects that are in motion relative to the observer, particularly during changes in ambient lighting from dark to light . These events generally start within two weeks of the administration of crizotinib and improve with time without the need to discontinue treatment. However, these adverse effects can affect the quality of life of patients.
The cause of these visual disturbances, which are unique to crizotinib, remains unknown. In recent studies examining patients treated with alectinib, which is a newly established and more specific inhibitor of ALK, the frequency of adverse effects (including visual disorders) was significantly lower than that for crizotinib [20,21]. In addition, visual disorders did not occur in patients treated with an inhibitor of MET, which is one of the targets of crizotinib .
Since the visual pathway is a complex system, visual disorders can occur at multiple levels, such as the retina, the lateral geniculate nucleus, and the primary visual cortex. In the present study, to examine whether the retina can be a target of drugs and whether the actions of drugs on retinal ganglion cells can predict differences in the incidences of adverse effects, we compared the actions of crizotinib and alectinib on the activities of retinal ganglion cells in the mouse retina using multi-electrode array recording.
Materials and Methods
The research protocol was approved by the Animal Experiments Ethical Review Committee of Nippon Medical School. The samples and methods used in the present experiments were essentially the same as those used in a previous paper . Mice (C57BL6, 6 weeks to 5 months old, male or female) dark adapted for 30–60 min were killed by cervical dislocation. Retina was isolated under dim red light and kept in oxygenated Ringer’s solution (in mM: NaCl, 120; KCl, 3.1; CaCl2, 2; MgSO4, 1; NaH2PO4, 0.5; NaHCO3, 23; glucose, 20; pH adjusted to 7.4–7.5 when bubbled with 95% O2−5% CO2) in the dark at room temperature until use. During the recordings, the retina was continuously superfused with oxygenated Ringer’s solution.
A piece of retina (3–6 mm per side) was placed ganglion cell side-down on a multi-electrode array (MED-P2H07A; Panasonic) and perfused with oxygenated Ringer’s solution (1 mL/min). The recorded extracellular action potentials were amplified 1000-fold, band-pass filtered (0.1–10 kHz), and sampled with a computer at 20 kHz. The action potentials of individual cells were identified using an off-line analysis with custom-developed software . Drugs were applied by bath application. Crizotinib was purchased from LC Laboratories (MA, USA). Alectinib was obtained from Chugai Pharmaceutical (Tokyo, Japan). The concentrations of crizotinib (1.0 μM) and alectinib (1.0 μM) used in the present study were almost equal to the Cmax (maximum plasma concentration) values, which were measured in repeated-dose studies [21,25]. All the experiments were performed at room temperature.
Classification of retinal ganglion cells
The retina was stimulated using spatially uniform white illumination switching between 0.7 mW/ m2 (dark stimulation) and 17 mW⁄ m2 (bright stimulation) at 0.5 Hz. The action potentials recorded for 60 s (30 cycles of light stimulation) before drug application were pooled and used to calculate the mean firing rates during bright stimulation (fbright) and dark stimulation (fdark). When the mean firing rate was less than 1 Hz before drug application, the cells were not used for further analysis. For each stimulation, the action potentials in a 1-second window of bright stimulation or dark stimulation, respectively, starting at 50 ms after onset were used to calculate the fbright or fdark values. The stimulus preference index (SPI) was calculated using the following formula: (1) where pref is the mean firing rate with the higher frequency between that for fbright and that for fdark, and n.pref is the mean firing rate with the lower frequency. If the SPI was equal to or higher than 0.67 and pref was the rate for fbright, the cells were classified as ON type retinal ganglion cells (ON-cells). If the SPI was equal to or higher than 0.67 and pref was the rate for fdark, the cells were classified as OFF type retinal ganglion cells (OFF-cells). Cells not classified as either ON- or OFF-cells were classified as ON-OFF type retinal ganglion cells (ON-OFF cells). In some of the experiments, we also calculated the SPI during and after the application of drugs using a method similar to that described above.
To assess the actions of the drugs on the firing rate, we calculated the mean firing rate using the following method. First, we calculated the mean firing rate (rpre) and the standard deviation (spre) before drug application using the same data set as that used for the SPI analysis. To calculate spre, we sectioned the data before drug application into 10 bins (3 cycles each [6 s]) and used the following equation: (2) where n is total number of bins and x is the mean firing rate of the individual bin. We also calculated the mean firing rate during (rdrug) and after (rpost) drug application. The index, X, was calculated using the following formula: (3) If X was larger than twice the value of spre, (corresponding to P < 0.05), the action of the drug on the firing rate was judged as “significant”.
To assess the stimulus information transferred by the retinal ganglion cells, the spike triggered average stimulus (STA or F(T)) was calculated using the light stimulus information. In this calculation, light stimulation for 1 s preceding a spike was binned with a resolution of 50 ms. The stimulus during a time interval (T) before the onset of an individual action potential was averaged according to a previously reported protocol (Dayan and Abbott, 2001) and the following equation: (4) where n is the number of spikes, t is the time when the spikes occurred, and s(t) is the light intensity as a function of time. The light intensity for this analysis was defined as 1 for bright stimulation and 0 for dark stimulation.
When the groups had equal variance, we adopted a parametric test. For samples with different variances, we adopted a nonparametric test. Comparisons of variance between groups were performed using the F test.
Reverse transcription PCR and quantitative RT-PCR
Total RNA was extracted from mouse retina (C57BL6, 8 weeks) using ISOGEN reagent (Nippongene, Japan). The RNA was pooled in a PCR tube containing a ribonuclease (RNase) inhibitor (TaKaRa) and Primer Mix (ReverTra Ace qPCR RT Kit; Toyobo). The PCR tube was heated at 75°C for 5 min and cooled on ice for 1 min; RT Enzyme Mix and 5xRT Buffer (ReverTra Ace qPCR RT Kit; Toyobo) were then added. Reverse transcription (RT) into cDNA was performed using TaKaRa PCR Thermal Cycler Dice Standard (TaKaRa). RT was performed at 30°C for 10 min and then at 42°C for 60 min. After stopping the reaction by heating at 75°C for 15 min, the reaction mixture was kept at 4°C and stored at -80°C until use. A relative quantitative PCR (qPCR) analysis was performed using the SYBR Premix Ex Taq II (TaKaRa) and Thermal Cycler Dice real-time System Single (TaKaRa) following the manufacturer’s instructions. ß-actin (ACTB), a housekeeping gene, was used as an internal reference, and distilled water was used as a negative control. The primer sequences, product sizes, and accession numbers are listed in Table 1. For each cDNA, relative qPCR was performed in triplets. The relative expression levels of mouse anaplastic lymphoma kinase (ALK), MET, and ROS1 were compared with that of ACTB using the ΔΔCT method. The PCR products were separated using electrophoresis on 2% agarose gels and were visualized using ethidium bromide staining under UV irradiation.
Actions of crizotinib and alectinib in the retina
To examine whether crizotinib modifies visual function at the retinal level, we collected 101 retinal ganglion cells (48 ON-cells, 47 OFF-cells, and 6 ON-OFF cells) (Table 2) and examined the actions of crizotinib on the firing rate. Among the 101 cells that were examined, crizotinib changed the firing rate in 44 cells (43.6%). The actions of crizotinib on the firing rate were classified into no change type (Fig 1A), increase type (Fig 1B), and decrease type (Fig 1C). Among the cells that showed a change in the firing rate (increase or decrease type), the change in the firing rate occurred soon after the application of crizotinib. The actions of crizotinib on the firing rate were reversible.
The timing of the drug application is indicated by the bar above the traces. The drug concentration was 1.0μM for both crizotinib and alectinib. The results for no change-type (A, D), increase-type (B, E), and decrease-type (C, F) cells are shown. The retina was repeatedly exposed to a set of light stimuli (1-s bright stimulation and 1-s dark stimulation at a frequency of 0.5 Hz). The ordinate shows the average firing rate for 10 cycles of stimuli (20 s).
We performed a similar analysis for alectinib to compare the severity of visual disorders induced by crizotinib and alectinib. Among the 87 cells that were examined (37 ON-cells, 47 OFF-cells, and 3 ON-OFF cells) (Table 2), alectinib changed the firing rate (increase or decrease type) in 21 cells (24.1%). The actions of alectinib on the firing rate were also classified into three types (Fig 1D–1F). The actions of alectinib on the firing rate occurred soon after the application of alectinib and were reversible.
Since both crizotinib and alectinib showed three different types of actions on the firing rate, we directly compared whether the actions of crizotinib and the actions of alectinib on the firing rate were the same in individual cells. We selected cells in which we were able to examine the actions of both crizotinib and alectinib successfully in the same cell and classified these cells into 5 categories (Table 3). Among the 70 cells (30 ON-cells, 37 OFF-cells, and 3 ON-OFF cells) that were examined, the actions of the drugs on the firing rate were the same in 52 cells (Category “S” + “N”), while opposite actions on the firing rate were observed in only 2 cells (Category “O”). None of the cells showed a change in the firing rate in response to alectinib only (Category “A”). The remaining 16 cells showed a change in the firing rate in response to crizotinib only (Category “C”). These findings suggest that the actions of crizotinib and alectinib on the firing rates of individual cells are basically the same (correlation coefficient, 0.51; P < 0.001). However, a significant difference in the number of affected cells was observed between these two drugs (P < 0.01, Chi-squared test). Alectinib affected 11 cells (15.7%, Category “S” + “A”), while crizotinib affected 27 cells (38.6%, Category “S” + “C”). The difference in the number of affected cells between the crizotinib and alectinib groups may explain the lower incidence of visual disorders induced by alectinib.
Actions of crizotinib and alectinib on stimulus preference
Next, we examined the actions of crizotinib and alectinib on stimulus preference. The effects of drugs on stimulus preference might be related to the severe visual disorder, since a change in the preference of OFF-cells implies that dark stimuli are not being detected properly (and vice versa for ON-cells and bright stimuli). Fig 2A and 2B shows the averaged firing rates of representative cells exhibiting severe SPI changes induced by crizotinib. In Fig 2A, the cell responded to dark stimuli before drug application (black solid line) (SPI = 0.92). However, once crizotinib was applied to the cell, the cell began to respond to both dark and bright stimuli (red line) (SPI = 0.61), indicating that the OFF-cell had begun to behave like an ON-OFF cell. The actions of crizotinib on the firing rate were reversible (black dotted line) (SPI = 0.82). In contrast, the cell shown in Fig 2B originally responded to both dark and bright stimuli (black solid line) (SPI = 0.61). During the application of crizotinib, the cell did not respond to bright stimuli (red line) (SPI = 0.91), suggesting that the cell type had changed from an ON-OFF cell to an OFF-cell. The actions of crizotinib on the firing rate were also reversible (black dotted line) (SPI = 0.59). Thus, the change in SPI was bidirectional.
(A and B) Post-stimulus time histogram before (pre), during (crizotinib), and after (wash) the application of 1.0μM of crizotinib in an OFF-cell (A) and in an ON-OFF cell (B). The bin size for the histogram was 50 ms. (C and D) Cumulative distributions of the differences in SPI for crizotinib and alectinib. The difference in SPI was calculated from the SPI values evaluated before and during drug application. The cells were divided into “Decrease” type (C) and “Increase” type (D) according to the change in the SPI. The difference in (D) was an absolute value. (E and F) STA before (pre), during (crizotinib), and after (wash) the application of crizotinib in the cells shown in Figs 2A (E) and B (F). The amplitude “A” was defined as the difference in light intensity between the maximum and the minimum (double-headed arrow). (G and H) Plot of the amplitude “A” before (pre) and during drug application (drug) for the cells shown in Table 4. The cells were divided into “Decrease” type (G) and “Increase” type (H). **P < 0.01; *** P < 0.001; paired t-test.
To assess the effect of crizotinib or alectinib on the SPI, we calculated the SPI before (SPIpre) and during (SPIdrug) drug application for all the cells shown in Table 2. First, we classified the cells into three groups based on the difference between SPIpre and SPIdrug for individual cells. “Decrease” means that the drug decreased the SPI (46 cells for crizotinib and 41 cells for alectinib), while “Increase” means that the drug increased the SPI (44 cells for crizotinib and 44 cells for alectinib). In some of the cells, the difference between SPIpre and SPIdrug was not significant (“No change” type; 11 cells for crizotinib and 2 cells for alectinib). For both the “Decrease” and “Increase” types, the cumulative distributions of crizotinib and alectinib overlapped each other at some point. However, at the point where the cumulative distribution of alectinib had almost reached a plateau (arrow), that of crizotinib was not yet saturated. The difference in the cumulative distributions of crizotinib and alectinib means that crizotinib induced a greater change in the SPI than alectinib. Table 4 shows the numbers of cells exhibiting a larger difference in the SPI than the difference indicated by the arrow (Fig 2C and 2D). Here, we extracted severely affected cells from the “Decrease” and “Increase” categories, and cells with a smaller difference than that indicated by the arrow were classified as a “Mild change” group. Twenty (2 + 0 + 0 + 0 + 9 + 5 + 3 + 1, in Table 4) cells were severely affected by crizotinib, while only 7 (0 + 0 + 4 + 1 + 2 + 0) cells were severely affected by alectinib. The number of severely affected cells differed significantly between the drugs (P < 0.05, Chi-squared test), supporting the higher incidence of severe visual disorder in patients treated with crizotinib. A large change in the SPI was not always associated with a change in the firing rate (8 out of 20 cells for crizotinib, 4 out of 7 cells for alectinib).
Further analysis of cells with large SPI differences
How does the change in the SPI modify the transferred visual information? To visualize the transferred visual information in the presence and absence of drugs, we used the STA. The cell (“Decrease” type) shown in Fig 2A tended to respond when the light intensity decreased greatly (Fig 2E), indicating that the cell mainly fired during dark stimulation before drug application (pre). During the application of crizotinib, the cell tended to respond to relatively steady light stimuli, indicating that the cell fired in response to both dark and bright stimuli. To analyze the actions of the drugs on the transferred information, the amplitude “A” (Fig 2E, double-headed arrow) was defined as the difference between the maximum and minimum STA intensity. The amplitude decreased in all the cells and became significantly small during drug application (n = 7, P < 0.01, paired t-test, Fig 2G). On the other hand, the cell (“Increase” type) shown in Fig 2B initially had a low SPI, indicating that the cell responded to both dark and bright stimuli (Fig 2F). During the application of crizotinib, the cell lost its response to bright stimuli (Fig 2B, arrow); consequently, an increase in the SPI was observed. In the “Increase” cell type, the amplitude “A” became significantly large during drug application (n = 20, P < 0.001, paired t-test, Fig 2H). These changes indicate that the property of the transferred visual information differed during drug application. Since only a few cells were examined for alectinib, we did not compare the actions between crizotinib and alectinib.
Ganglion cells must correctly detect light stimuli (signals) under the presence of various background light sources (noise). Here, we regarded the firing rate for the preferred stimulation as the signal and that for non-preferred stimulation as noise and calculated the signal to noise ratio (S/N) of the cells, as shown in Table 4. After drug application, the S/N ratio decreased significantly from 16.13 ± 8.23 to 2.63 ± 0.77 (mean ± SEM) in 6 OFF-cells, which exhibited a reduced SPI (P < 0.05, Wilcoxon signed-rank test), while it increased significantly from 5.71 ± 0.84 to 18.26 ± 5.55 (mean ± SEM) in 13 OFF-cells, which exhibited an increased SPI (P < 0.001, Wilcoxon signed-rank test). Therefore, crizotinib and alectinib might affect the spontaneous noise level.
Expression of mRNAs targeted by crizotinib or alectinib
To examine whether target receptors for crizotinib or alectinib exist in mouse retina, we performed qPCR for ALK, a target receptor of both crizotinib and alectinib, and for MET and ROS1, two additional target receptors of crizotinib. For ALK, MET, and ROS1, single bands of the expected sizes were detected (Fig 3A, Table 1). Among the three target receptors, the expression level of ALK was the highest and that of ROS1 was the lowest. The expression levels of ALK, MET, and ROS1 were lower than that of ACTB (Fig 3B). The absence of additional signal amplification was confirmed by the dissociation curve (data not shown).
In this experiment, we examined whether crizotinib or alectinib could induce visual disorders at the level of the retinal ganglion cells. We found that both crizotinib and alectinib disturbed the signal processing of retinal ganglion cells and that the functional disturbance induced by crizotinib was stronger than that induced by alectinib. Our data strongly support the idea that functional disturbance of the retinal ganglion cells is one possible source of visual disorder and that the magnitude of the functional disturbance may be a useful indicator for predicting the severity of visual disorders induced by newly synthesized drugs.
Effects of crizotinib and alectinib on firing rate and stimulus preference
The application of crizotinib or alectinib reversibly changed the firing rate and the stimulus preference to light stimulation in some cells. Changes in the firing rate were significantly more common during treatment with crizotinib than during treatment with alectinib. In addition, significantly more cells exhibited drastic changes in stimulus preference during treatment with crizotinib than during treatment with alectinib.
Clinically, visual disorders induced by crizotinib are more severe than those induced by alectinib. Experimentally, the firing rate is generally considered to convey information regarding the stimulus intensity [26,27]. For example, the firing rate of ON-cells increases with increasing light intensity. Thus, the firing rate reflects a quantitative change in the light stimuli. On the other hand, the stimulus preference reflects a qualitative change in light stimuli for the following reason. We used the SPI to characterize the ganglion cells based on the visual information that they transferred. When ON-cells exhibited a large reduction in SPI, the cells were re-classified as ON-OFF cells. The change in the SPI meant that the ON-cells could not respond to the proper light stimuli at the proper timing. Therefore, a change in stimulus preference can be interpreted as a qualitative change in light stimuli. We concluded that a qualitative index was a better indicator for assessing the severity of side effects, although large changes were observed both quantitatively and qualitatively during treatment with crizotinib.
Molecular targets of crizotinib and alectinib
Why was there a difference in the severity of visual disorders between crizotinib and alectinib? We confirmed the expressions of ALK, MET, and ROS1 mRNA (receptor tyrosine kinases that serve as therapeutic targets in non-small-cell lung cancers [19,28]), in the mouse retina (Fig 3). Immunoreactivity for ALK protein has been observed in mice . Both crizotinib and alectinib inhibit ALK at nanomolar concentrations, but the incidence of visual disorder is higher for crizotinib. Therefore, the high frequency of visual disorder induced by crizotinib is unlikely to be attributable to ALK inhibition. This idea is consistent with previous findings indicating that an ALK-selective inhibitor did not produce significant changes on an electroretinogram . Crizotinib also inhibits MET and ROS1 at nanomolar concentrations , while the inhibitory actions of alectinib on MET and ROS1 only occur at micromolar concentrations or higher [30,31]. However, the presence of MET  and ROS1 has not been confirmed at the protein level in the mouse retina. Therefore, it will be interesting to see if the actions of crizotinib on MET or ROS1 in the retina play a key role in the severe visual disorder.
Possible visual disorder in the retina
How do SPI disturbances modify our signal processing of visual scenes? We observed drastic changes in the SPI in a few OFF-cells. Since OFF-cells respond to dark stimuli and ON-cells respond to bright stimuli, edges with a sharp contrast are detected by the coordination of both ON- and OFF-cells. When the SPI of OFF-cells is drastically reduced, edges with a sharp contrast cannot be detected clearly, leading to confusion in higher visual centers. Therefore, SPI disturbances in the retina may be a source of the symptoms (such as diplopia and blurred vision) that sometimes occur in patients treated with crizotinib, and the transfer of incorrect signals from the retina may create confusion in higher visual centers.
The present study has some limitations that should be considered. In addition to using a mouse model, we did not examine the effects of the agents on higher visual centers, such as the lateral geniculate nucleus or the primary visual cortex. Thus, the present results may not concisely explain the visual disturbances experienced by patients treated with crizotinib. Furthermore, although the concentrations of the agents used in the present study were comparable to the Cmax level used in clinical situations, many unidentified factors may affect the actual drug concentrations in the retina. These factors may include differences in the concentration and/or clearance between vascular and intraocular regions as well as the protein binding capacity of the agents. All these issues should be taken into consideration when translating the results of our ex vivo experiments into clinical situations.
In conclusion, ALK-tyrosine kinase inhibitors affected the signal processing of light at the retinal ganglion cell level in an ex vivo mouse model, and the effects of crizotinib were severer than those of alectinib, possibly explaining the difference in adverse effects (visual disturbances) observed in clinical situations.
We thank Dr. T. Hosoya for providing the multi-electrode array system and Dr. S. A. Baccus for providing the spike-sorting program. We also thank Miss S. Usui and Mrs. A. Suzuki for conducting the experiments efficiently.
Conceived and designed the experiments: YT TI MK. Performed the experiments: TI AM MK. Analyzed the data: TI SI RK AM YT MK. Contributed reagents/materials/analysis tools: YT TI MK. Wrote the paper: TI SI RK AM YT MK. Obtained permission for use of alectinib: YT.
- 1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England journal of medicine 362: 2380–2388. pmid:20573926
- 2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. The New England journal of medicine 353: 123–132. pmid:16014882
- 3. Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Annals of oncology 16: 1425–1433. pmid:16012181
- 4. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al. (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. The Lancet Oncology 13: 528–538. pmid:22452896
- 5. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Annals of oncology 18: 317–323. pmid:17079694
- 6. Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. (2013) PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Journal of clinical oncology 31: 2895–2902. pmid:23835707
- 7. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology 11: 121–128. pmid:20022809
- 8. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology 12: 735–742. pmid:21783417
- 9. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England journal of medicine 363: 1693–1703. pmid:20979469
- 10. Gambacorti-Passerini C, Messa C, Pogliani EM (2011) Crizotinib in anaplastic large-cell lymphoma. The New England journal of medicine 364: 775–776. pmid:21345110
- 11. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448: 561–566. pmid:17625570
- 12. Mano H (2008) Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer science 99: 2349–2355. pmid:19032370
- 13. Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, Ueno T, et al. (2008) A mouse model for EML4-ALK-positive lung cancer. Proceedings of the National Academy of Sciences of the United States of America 105: 19893–19897. pmid:19064915
- 14. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, et al. (2011) Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. Journal of thoracic oncology 6: 942–946. pmid:21623265
- 15. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. (2012) ROS1 rearrangements define a unique molecular class of lung cancers. Journal of clinical oncology 30: 863–870. pmid:22215748
- 16. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The Lancet Oncology 13: 1011–1019. pmid:22954507
- 17. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. The New England journal of medicine 368: 2385–2394. pmid:23724913
- 18. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England journal of medicine 371: 2167–2177. pmid:25470694
- 19. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. The New England journal of medicine 371: 1963–1971. pmid:25264305
- 20. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, et al. (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. The Lancet Oncology 15: 1119–1128. pmid:25153538
- 21. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, et al. (2013) CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. The Lancet Oncology 14: 590–598. pmid:23639470
- 22. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Vas Laethem JL, et al. (2013) Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. The Lancet Oncology 14: 55–63. pmid:23182627
- 23. Kaneda M, Ishii T, Hosoya T (2008) Pathway-dependent modulation by P2-purinoceptors in the mouse retina. The European journal of neuroscience 28: 128–136. pmid:18616561
- 24. Meister M, Pine J, Baylor DA (1994) Multi-neuronal signals from the retina: acquisition and analysis. Journal of neuroscience methods 51: 95–106. pmid:8189755
- 25. Phizer Inc. (2012) Crizotinib Interview form, 3rd edition.
- 26. Adrian ED, Zotterman Y (1926) The impulses produced by sensory nerve-endings: Part II. The response of a Single End-Organ. The Journal of physiology 61: 151–171. pmid:16993780
- 27. Rieke F WD, de Ruyter van Steveninck R, Bialek W (1997) Spikes: exploring the neural code. Cambridge, MA: MIT press.
- 28. Perez CA, Velez M, Raez LE, Santos ES (2014) Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation. Lung cancer 84: 110–115. pmid:24598368
- 29. Liu CN, Mathialagan N, Lappin P, Fortner J, Somps C, Seitis G, et al. (2015) Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition. Toxicological sciences 143: 116–125. pmid:25326243
- 30. Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, et al. (2014) Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Molecular cancer therapeutics 13: 2910–2918. pmid:25349307
- 31. Chugai Pharmaceutical Co. Ltd. (2014) Alectinib Interview form, 2nd edition.